Stockwatch: Pie in the Sky
This article was originally published in Scrip
Gilead Sciences provided a mid-week earnings announcement explaining that all its major products sold well last quarter, including nearly $140m from the recently launched Sovaldi (sofosbuvir) for HCV infection, culminating in a slight beat of analysts' consensus earnings estimates. Having dominated HIV therapy, Gilead looks likely to do the same thing with HCV and even add a further string to its bow: oncology (scripintelligence.com, 5 February 2014).
You may also be interested in...
Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air.
Drugs that have failed in clinical studies often come back for another go, making the same mistakes for a new cohort of investors who missed the first failure. The global pandemic is also enabling this for once- or twice-failed drugs.
Batsu is the Japanese term for games that have penalties, unlike those which are just for fun. Seasoned investors are well aware of the risks of drug and vaccine development but many investors new to the sector are just learning of the downsides.